Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
US Army
Farmers Insurance
Moodys
US Department of Justice
Deloitte

Generated: July 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,744,170

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,744,170 protect, and when does it expire?

Patent 9,744,170 protects VIEKIRA XR and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 9,744,170
Title:Solid antiviral dosage forms
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
Inventor(s): Miller; Jonathan M. (Lindenhurst, IL), Morris; John B. (Grayslake, IL), Sever; Nancy E. (Northbrook, IL), Schmitt; Eric A. (Libertyville, IL), Gao; Ping X. (Highland Park, IL), Shi; Yi (Libertyville, IL), Gao; Yi (Vernon Hills, IL), Liepold; Bernd (Dossenheim, DE), Moosmann; Anna (Winterbach, DE), Pauli; Mirko (Ludwigshafen, DE), Durak; Fatih (Ludwigshafen, DE), Kessler; Thomas (Schifferstadt, DE), Hoelig; Peter (Waechtersbach, DE), Rosenblatt; Karin (Mannheim, DE), Kostelac; Drazen (Mannheim, DE), Gokhale; Rajeev (Singapore, SG), Costello; Mark (Chicago, IL), Knable; Carl (Elmhurst, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:15/073,767
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,744,170
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,744,170

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cipla
Deloitte
UBS
Moodys
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.